chatgpt: One nuance: “two vaccinations” is now somewhat dated internationally, because GOLD 2026 recommends influenza, COVID-19, pneumococcal, and additional vaccines according to age/risk and local guidelines.
maybe research and add this to extra
Vaccinations are important for patients with COPD,
who are at increased risk of respiratory and other
infections. (www.immune.org.nz)
• Yearly influenza vaccination reduces the risk of
serious illness and death and should be actively
promoted to patients with COPD.
• COVID-19 vaccination should be encouraged to
reduce the risk of severe COVID-19 and related
complications.
• Pneumococcal vaccination reduces the risk of
pneumonia and exacerbations, but is not currently
funded for COPD patients in New Zealand.
‒ Two types of pneumococcal vaccine are approved
for use. A suggested schedule is one dose of
13-valent protein conjugate vaccine (PCV13) given
first, followed at least eight weeks later by the first
dose of 23-valent polysaccharide vaccine (23PPV).
A second dose of 23PPV is given a minimum of
five years later. A maximum of 3 doses of 23PPV is
recommended in an adult lifetime.
• Respiratory syncytial virus (RSV) vaccine is now
available but currently not funded in New Zealand.
A single dose is recommended for patients over
50 years with COPD. RSV vaccination can reduce the
risk of hospitalisation due to RSV disease. The need
for revaccination is not yet clear.
• It is recommended that other vaccinations are kept
up to date including pertussis/whooping cough
(funded for over 65 years and over 45 years in some
people) and herpes zoster/shingles (funded at age 65).